Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned ( 1:1 ) to 6 cycles maximum ( 21 days/cycle ) of pemetrexed 500mg/m ( 2 ) + cisplatin 75mg/m ( 2 ) ( day 1 ) , or gemcitabine 1250mg/m ( 2 ) ( days 1 and 8 ) + cisplatin 75mg/m ( 2 ) ( day 1 ) .